Patents Assigned to STEMIRNA (SHANGHAI) BIOTECHNOLOGY CO. LTED.
  • Formulations and methods for the treatment of cancers
    Patent number: 11278524
    Abstract: The present invention is directed to a formulation for treating cancer comprising an androgen receptor signaling inhibitor and a B-cell-lymphoma-2 inhibitor, which may further comprising a Bromodomain-and-Extra-Terminal protein inhibitor or a phosphoinositide 3-kinase inhibitor.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 22, 2022
    Assignee: STEMIRNA (SHANGHAI) BIOTECHNOLOGY CO. LTED.
    Inventors: Dean G. Tang, Xin Chen